Clinical trial
A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients…
NCT00336700 · Herbert J. Zeh, III MD, FACS, Other · Terminated
Key facts
| NCT number | NCT00336700 |
|---|---|
| Title | A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer |
| Official title | A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer |
| Lead sponsor | Herbert J. Zeh, III MD, FACS, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine, Erlotinib |
| Enrollment | 25 |
| Start date | Jun 1, 2006 |
| Primary completion | Oct 1, 2011 |
| Completion | Nov 1, 2011 |
| First posted | Jun 14, 2006 |
| Last update posted | Sep 19, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: